References
- Charlemagne A, Blacher J, Cohen A, et al. Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis 2011;104:115-24
- Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke J Cereb Circ 2005;36:1115-19
- Brüggenjürgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health J Int Soc Pharmacoeconomics Outcomes Res 2007;10:137-43
- Ghatnekar O, Glader E-L. The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001. Value Health J Int Soc Pharmacoeconomics Outcomes Res 2008;11:862-8
- Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke J Cereb Circ 2001;32:392-8
- Le Heuzey J-Y, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004;147:121-6
- Le Heuzey J-Y, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014;111:833-41
- Tendera M, Syzdół M, Parma Z. ARISTOTLE RE-LYs on the ROCKET. What’s new in stroke prevention in patients with atrial fibrillation? Cardiol J 2012;19:4-10
- Bushnell CD, Matchar DB. Pharmacoeconomics of atrial fibrillation and stroke prevention. Am J Manag Care 2004;10(3Suppl):S66-S71
- Szucs TD, Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost JTH 2006;4:1180-5
- Boulanger L, Kim J, Friedman M, et al. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 2006;60:258-64
- Beinema M, Brouwers JRBJ, Schalekamp T, et al. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008;100:1052-7
- Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy. Chest 2012;141(2Suppl):e152S-e184S
- Tuppin P, de Roquefeuil L, Weill A, et al. French national health insurance information system and the permanent beneficiaries sample. Rev Dépidémiologie Santé Publique 2010;58:286-90
- Moulis G, Lapeyre-Mestre M, Palmaro A, et al. French health insurance databases: What interest for medical research? Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne 2015;36:411-17
- Martin-Latry K, Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 2010;19:256-65
- Belhassen M, Demoly P, Bloch-Morot E, et al. Costs of perennial allergic rhinitis and allergic asthma increase with severity and poor disease control. Allergy 2016;72:948-58
- Caisse Nationale d’Assurance Maladie. Nouveaux anti-coagulants oraux: une étude de l’Assurance Maladie souligne la dynamique forte de ces nouveaux médicaments et la nécessité d’une vigilance accrue dans leur utilisation; CNAM, France: Etude de l’Assurance Maladie sur l’utilisation des nouveaux anti-coagulants orau. 2013
- de Pouvourville G. Comment améliorer le suivi des AVK et pour quel coût? Arch Cardiovasc Dis Suppl 2016;8:169-73
- Detournay B. Coût direct des AVK en France. Arch Cardiovasc Dis Suppl 2016;8:174-9
- ANSM AN de la S. Bon usage des médicaments antivitamine K (AVK): actualisation-Juillet; ANSM, France: Bon usage des médicaments antivitamine K (AVKI) : Actualisation - Juillet 2012. 2012
- Moulis G, Lapeyre-Mestre M, Palmaro A, et al. French health insurance databases: What interest for medical research? Rev Med Interne 2015;36:411-17
- Ansolabehere X, Augier G. Cost of visits associated with management of international normalized ratio (INR) results in atrial fibrillation (AF) patients treated with Vitamin K Antagonist (VKA). Value in Health 2017